Telmisartan: a review of its pharmacodynamic and pharmacokinetic properties

Bibliography

• Kannel WB, Dawber TR, Kagan A, Factors of risk in the development of coronary heart disease – six year follow-up experience. The Framingham Study. Ann Intern Med 1961;55:33-50
   PubMed Web of Science ®Google Scholar
• Jacobson HR. Chronic renal failure: pathophysiology. Lancet 1991;338:419-23
   PubMed Web of Science ®Google Scholar
• Laragh JH, Baer L, Brunner HR, Renin, angiotensin and aldosterone system in pathogenesis and management of hypertensive vascular disease. Am J Med 1972;52:633-52
   PubMed Web of Science ®Google Scholar
• Hollander W. Role of hypertension in atherosclerosis and cardiovascular disease. Am J Cardiol 1976;38:786-800
   PubMed Web of Science ®Google Scholar
• Crowley SD, Gurley SB, Herrera MJ, Angiotensin II causes hypertension and cardiac hypertrophy through its receptors in the kidney. Proc Natl Acad Sci USA 2006;103:17985-90
   PubMed Web of Science ®Google Scholar
• Schwabe U, Paffrath D. 2008 Report on drug prescription. New York, Springer Publishing Group; 2006. p. 247-72
   Google Scholar
• Benndorf RA, Boger RH. Pleiotropic effects of telmisartan: still more to come? J Hypertens 2008;26:854-6
   PubMed Web of Science ®Google Scholar
• Battershill AJ, Scott LJ. Telmisartan: a review of its use in the management of hypertension. Drugs 2006;66(1):51-83
   PubMed Web of Science ®Google Scholar
• Telmisartan (Micardis®). Physicians' desk reference. 60th edition. Montvale, NJ, Medical Economics; 2005. p. 997-9
   Google Scholar
• EMEA document regarding the approval of telmisartan by the European commission. (Dok.-Ref.: EMA/829297/2009; EMEA/H/C/210). Available from: http://www.ema.europa.eu/humandocs/PDFs/EPAR/Pritor/198798de1.pdf. [Last accessed 31 March 2010]
   Google Scholar
• Micardis Briefing document for the Cardiovascular and Renal Drugs Advisory Committee (FDA) from July 28, 2009. Available from: http://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/ CardiovascularandRenalDrugsAdvisory Committee/UCM173529.pdf. [Last accessed 31 March 2010]
   Google Scholar
• Wienen W, Hauel N, Van Meel JC, Pharmacological characterization of the novel nonpeptide angiotensin II receptor antagonist, BIBR 277. Br J Pharmacol 1993;110:245-52
   PubMed Web of Science ®Google Scholar
• Benson SC, Pershadsingh HA, Ho CI, Identification of telmisartan as a unique angiotensin II receptor antagonist with selective PPAR-gamma-modulating activity. Hypertension 2004;43:993-1002
   PubMed Web of Science ®Google Scholar
• Schupp M, Janke J, Clasen R, Angiotensin type 1 receptor blockers induce peroxisome proliferator-activated receptor-gamma activity. Circulation 2004;109:2054-7
   PubMed Web of Science ®Google Scholar
• Benndorf RA, Rudolph T, Appel D, Telmisartan improves insulin sensitivity in nondiabetic patients with essential hypertension. Metabolism 2006;55:1159-64
   PubMed Web of Science ®Google Scholar
• Bajcetic M, Benndorf RA, Appel D, Pharmacokinetics of oral doses of telmisartan and nisoldipine, given alone and in combination, in patients with essential hypertension. J Clin Pharmacol 2007;47:295-304
   PubMed Web of Science ®Google Scholar
• Yu YH, Ginsberg HN. Adipocyte signaling and lipid homeostasis: sequelae of insulin-resistant adipose tissue. Circ Res 2005;96:1042-52
   PubMed Web of Science ®Google Scholar
• Clemenz M, Frost N, Schupp M, Liver-specific peroxisome proliferator-activated receptor alpha target gene regulation by the angiotensin type 1 receptor blocker telmisartan. Diabetes 2008;57:1405-13
   PubMed Web of Science ®Google Scholar
• Fruchart JC. Peroxisome proliferator-activated receptor-alpha (PPARalpha): at the crossroads of obesity, diabetes and cardiovascular disease. Atherosclerosis 2009;205:1-8
   PubMed Web of Science ®Google Scholar
• Hsueh WA, Jackson S, Law RE. Control of vascular cell proliferation and migration by PPAR-gamma: a new approach to the macrovascular complications of diabetes. Diabetes Care 2001;24:392-7
   PubMed Web of Science ®Google Scholar
• Cianchetti S, Del Fiorentino A, Colognato R, Anti-inflammatory and anti-oxidant properties of telmisartan in cultured human umbilical vein endothelial cells. Atherosclerosis 2008;198:22-8
   PubMed Web of Science ®Google Scholar
• Benson SC, Iguchi R, Ho CI, Inhibition of cardiovascular cell proliferation by angiotensin receptor blockers: are all molecules the same? J Hypertens 2008;26:973-80
   PubMed Web of Science ®Google Scholar
• Benndorf RA, Appel D, Maas R, Telmisartan improves endothelial function in patients with essential hypertension. J Cardiovasc Pharmacol 2007;50:367-71
   PubMed Web of Science ®Google Scholar
• Stangier J, Schmid J, Turck D, Absorption, metabolism, and excretion of intravenously and orally administered [14C]telmisartan in healthy volunteers. J Clin Pharmacol 2000;40:1312-22
   PubMed Web of Science ®Google Scholar
• Stangier J, Su CA, Roth W, Pharmacokinetics of orally and intravenous administered telmisartan in healthy young and elderly volunteers and in hypertensive patients. J Int Med Res 2000;28:149-72
   PubMed Web of Science ®Google Scholar
• Ishiguro N, Maeda K, Kishimoto W, Predominant contribution of OATP1B3 to the hepatic uptake of telmisartan, an angiotensin II receptor antagonist, in humans. Drug Metab Dispos 2006;34:1109-15
   PubMed Web of Science ®Google Scholar
• Ishiguro N, Maeda K, Saito A, Establishment of a set of double transfectants coexpressing organic anion transporting polypeptide 1B3 and hepatic efflux transporters for the characterization of the hepatobiliary transport of telmisartan acylglucuronide. Drug Metab Dispos 2008;36:796-805
   PubMed Web of Science ®Google Scholar
• Micardis full prescribing information of the EMEA. Available from: http://www.ema.europa.eu/humandocs/PDFs/EPAR/Micardis/emea-combined-h209en.pdf. [Last accessed 5 May 2010]
   Google Scholar
• Micardis full prescribing information of the FDA. Available from: http:// www.accessdata.fda.gov/drugsatfda_docs/label/2009/020850s025lbl.pdf. [Last accessed 5 May 2010]
   Google Scholar
• Harris RZ, Benet LZ, Schwartz JB. Gender effects in pharmacokinetics and pharmacodynamics. Drugs 1995;50:222-39
   PubMed Web of Science ®Google Scholar
• Stangier J, Su Chung-An PF, Brickl R, Pharmacokinetics of single-dose telmisartan 120 mg given during and between hemodialysis in subjects with severe renal insufficiency: comparison with healthy volunteers. J Clin Pharmacol 2000;40:1365-72
   PubMed Web of Science ®Google Scholar
• Verbeeck RK, Musuamba FT. Pharmacokinetics and dosage adjustment in patients with renal dysfunction. Eur J Clin Pharmacol 2009;65:757-73
   PubMed Web of Science ®Google Scholar
• Stangier J, Su Chung-An PF, Schondorfer G, Pharmacokinetics and safety of intravenous and oral telmisartan 20 mg and 120 mg in subjects with hepatic impairment compared with healthy volunteers. J Clin Pharamcol 2000;40:1355-64
   Web of Science ®Google Scholar
• Unger T, Kaschina E. Drug interactions with angiotensin receptor blockers: a comparison with other antihypertensives. Drug Saf 2003;26:707-20
   PubMed Web of Science ®Google Scholar
• Weiss J, Sauer A, Divac N, Interaction of angiotensin receptor type 1 blockers with ATP-binding cassette transporters. Biopharm Drug Dispos 2010;31:150-61
   PubMed Web of Science ®Google Scholar
• Stangier J, Su C-APF. Pharmacokinetics of repeated oral doses of amlodipine and amlodipine plus telmisartan in healthy volunteers. J Clin Pharmacol 2000;40:1347-54
   PubMed Web of Science ®Google Scholar
• FDA safety information regarding the clinical interaction of telmisartan and ramipril. Available from: http://www.fda.gov/Safety/MedWatch/SafetyInformation/ucm182000.htm. [Last accessed 31 March 2010]
   Google Scholar
• Yusuf S, Teo KK, Pogue J, The ONTARGET investigators. Telmisartan, ramipril, or both in patients at high risk for vascular events. N Engl J Med 2008;358:1547-59
   PubMed Web of Science ®Google Scholar
• Stangier J, Su C-APF, Hendriks MGC, Steady-state pharmacodynamics and pharmacokinetics of warfarin in the presence and absence of telmisartan in healthy male volunteers. J Clin Pharmacol 2000;40:1331-7
   PubMed Web of Science ®Google Scholar
• Stangier J, Su C-APF, Fraunhofer A, Pharmacokinetics of acetaminophen and ibuprofen when coadministered with telmisartan in healthy volunteers. J Clin Pharmacol 2000;40:1338-46
   PubMed Web of Science ®Google Scholar
• Yong C-L, Dias VC, Stangier J. Multiple-dose pharmacokinetics of telmisartan and of hydrochlorothiazide following concurrent administration in healthy subjects. J Clin Pharmacol 2000;40:1323-30
   PubMed Web of Science ®Google Scholar
• Nishino A, Kato Y, Igarashi T, Both cMOAT/MRP2 and another unknown transporter(s) are responsible for the biliary excretion of glucuronide conjugate of the nonpeptide angiotensin II antagonist, telmisartan. Drug Metab Dispos 2000;28:1146-8
   PubMed Web of Science ®Google Scholar
• Miura M, Satoh S, Inoue K, Telmisartan pharmacokinetics in Japanese renal transplant recipients. Clin Chim Acta 2009;399:83-7
   PubMed Web of Science ®Google Scholar
• Guo X, Chen XP, Cheng ZN, No effect of MDR1 C3435T polymorphism on oral pharmacokinetics of telmisartan in 19 healthy Chinese male subjects. Clin Chem Lab Med 2009;47:38-43
   PubMed Web of Science ®Google Scholar
• Chang C, Bahadduri PM, Polli JE, Rapid identification of P-glycoprotein substrates and inhibitors. Drug Metab Dispos 2006;34:1976-84
   PubMed Web of Science ®Google Scholar
• Fenner KS, Troutman MD, Kempshall S, Drug–drug interactions mediated through P-glycoprotein: clinical relevance and in vitro–in vivo correlation using digoxin as a probe drug. Clin Pharmacol Ther 2009;85:173-81
   PubMed Web of Science ®Google Scholar
• Kamiyama E, Nakai D, Mikkaichi T, Interaction of angiotensin II type 1 receptor blockers with P-gp substrates in Caco-2 cells and hMDR1-expressing membranes. Life Sci 2010;86:52-8
   PubMed Web of Science ®Google Scholar
• Stangier J, Su C-APF, Hendriks MGC, The effect of telmisartan on the steady-state pharmacokinetics of digoxin in healthy male volunteers. J Clin Pharmacol 2000;40:1373-9
   PubMed Web of Science ®Google Scholar
• Kearney PM, Whelton M, Reynolds K, Global burden of hypertension: analysis of worldwide data. Lancet 2005;365:217-23
   PubMed Web of Science ®Google Scholar
• Chobanian AV, Bakris GL, Black HR, Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. National Heart, Lung, and Blood Institute; National High Blood Pressure Education Program Coordinating CommitteeSeventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Hypertension 2003;42:1206-52
   PubMed Web of Science ®Google Scholar
• Neutel JM, Kolloch RE, Plouin PF, Telmisartan vs losartan plus hydrochlorothiazide in the treatment of mild-to-moderate essential hypertension – a randomised ABPM study. J Hum Hypertens 2003;17:569-75
   PubMed Web of Science ®Google Scholar
• Zhu JR, Bai J, Cai NS, Efficacy and safety of telmisartan vs. losartan in control of mild-to-moderate hypertension: a multicentre, randomised, double-blind study. Int J Clin Pract Suppl 2004;145:46-9
   PubMedGoogle Scholar
• Littlejohn T, Mroczek W, Marbury T, A prospective, randomized, open-label trial comparing telmisartan 80 mg with valsartan 80 mg in patients with mild to moderate hypertension using ambulatory blood pressure monitoring. Can J Cardiol 2000;16:1123-32
   PubMed Web of Science ®Google Scholar
• White WB, Lacourciere Y, Davidai G. Effects of the angiotensin II receptor blockers telmisartan versus valsartan on the circadian variation of blood pressure: impact on the early morning period. Am J Hypertens 2004;17:347-53
   PubMed Web of Science ®Google Scholar
• Smith DH. Comparison of angiotensin II type 1 receptor antagonists in the treatment of essential hypertension. Drugs 2008;68:1207-25
   PubMed Web of Science ®Google Scholar
• Stergiou GS, Efstathiou SP, Roussias LG, Mountokalakis TD. Blood pressure- and pulse pressure-lowering effects, trough:peak ratio and smoothness index of telmisartan compared with lisinopril. J Cardiovasc Pharmacol 2003;42:491-6
   PubMed Web of Science ®Google Scholar
• Smith DH. Treatment of hypertension with an angiotensin II-receptor antagonist compared with an angiotensin-converting enzyme inhibitor: a review of clinical studies of telmisartan and enalapril. Clin Ther 2002;24:1484-501
   PubMed Web of Science ®Google Scholar
• Alcocer L, Fernandez-Bonetti P, Campos E, Clinical efficacy and safety of telmisartan 80 mg once daily vs. atenolol 50 mg once daily in patients with mild-to-moderate hypertension. Int J Clin Pract Suppl 2004;145:35-9
   PubMedGoogle Scholar
• Lacourciere Y, Lenis J, Orchard R, A comparison of the efficacies and duration of action of the angiotensin II receptor blockers telmisartan and amlodipine. Blood Press Monit 1998;3:295-302
   PubMedGoogle Scholar
• Freytag F, Schelling A, Meinicke T, Telmisartan Hypertension Experience in a Randomized European Study Versus Atenolol Study Group. Comparison of 26-week efficacy and tolerability of telmisartan and atenolol, in combination with hydrochlorothiazide as required, in the treatment of mild to moderate hypertension: a randomized, multicenter study. Clin Ther 2001;23:108-23
   PubMed Web of Science ®Google Scholar
• Gil-Extremera B, Ma PT, Yulde J, The adjunctive effect of telmisartan in patients with hypertension uncontrolled on current antihypertensive therapy. Int J Clin Pract 2003;57:861-6
   PubMed Web of Science ®Google Scholar
• Yusuf S, Sleight P, Pogue J, Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. N Engl J Med 2000;342:145-53
   PubMed Web of Science ®Google Scholar
• Fox KM. EURopean trial On reduction of cardiac events with Perindopril in stable coronary Artery disease Investigators. Efficacy of perindopril in reduction of cardiovascular events among patients with stable coronary artery disease: randomised, double-blind, placebo-controlled, multicentre trial (the EUROPA study). Lancet 2003;362:782-8
   PubMed Web of Science ®Google Scholar
• Braunwald E, Domanski MJ, Fowler SE, PEACE Trial Investigators. Angiotensin-converting-enzyme inhibition in stable coronary artery disease. N Engl J Med 2004;351:2058-68
   PubMed Web of Science ®Google Scholar
• Pitt B, Segal R, Martinez FA, Randomised trial of losartan versus captopril in patients over 65 with heart failure (Evaluation of Losartan in the Elderly Study, ELITE). Lancet 1997;349:747-52
   PubMed Web of Science ®Google Scholar
• McMurray JJ, Ostergren J, Swedberg K, CHARM Investigators and Committees. Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function taking angiotensin-converting-enzyme inhibitors: the CHARM-Added trial. Lancet 2003;362:767-71
   PubMed Web of Science ®Google Scholar
• Teo K, Yusuf S, Sleight P, ONTARGET/TRANSCEND Investigators. Rationale, design, and baseline characteristics of 2 large, simple, randomized trials evaluating telmisartan, ramipril, and their combination in high-risk patients: the Ongoing Telmisartan Alone and in Combination with Ramipril Global Endpoint Trial/Telmisartan Randomized Assessment Study in ACE Intolerant Subjects with Cardiovascular Disease (ONTARGET/TRANSCEND) trials. Am Heart J 2004;148:52-61
   PubMed Web of Science ®Google Scholar
• Yusuf S, Teo K, Anderson C, Effects of the angiotensin-receptor blocker telmisartan on cardiovascular events in high-risk patients intolerant to angiotensin-converting enzyme inhibitors: a randomised controlled trial. Lancet 2008;372:1174-83
   PubMed Web of Science ®Google Scholar
• Diener HC, Sacco RL, Yusuf S, Prevention Regimen for Effectively Avoiding Second Strokes (PRoFESS) study group. Effects of aspirin plus extended-release dipyridamole versus clopidogrel and telmisartan on disability and cognitive function after recurrent stroke in patients with ischaemic stroke in the Prevention Regimen for Effectively Avoiding Second Strokes (PRoFESS) trial: a double-blind, active and placebo-controlled study. Lancet Neurol 2008;7:875-84
   PubMed Web of Science ®Google Scholar
• Ross SD, Akhras KS, Zhang S, Discontinuation of antihypertensive drugs due to adverse events: a systematic review and meta-analysis. Pharmacotherapy 2001;21:940-53
   PubMed Web of Science ®Google Scholar
• Michel MC, Bohner H, Koster J, Safety of telmisartan in patients with arterial hypertension: an open-label observational study. Drug Saf 2004;27:335-44
   PubMed Web of Science ®Google Scholar
• Neutel JM, Frishman WH, Oparil S, Comparison of telmisartan with lisinopril in patients with mild-to-moderate hypertension. Am J Ther 1999;6:161-6
   PubMedGoogle Scholar
• Williams B, Gosse P, Lowe L, PRISMA I Study Group. The prospective, randomized investigation of the safety and efficacy of telmisartan versus ramipril using ambulatory blood pressure monitoring (PRISMA I). J Hypertens 2006;24:193-200
   PubMed Web of Science ®Google Scholar
• Hannedouche T, Chanard J, Baumelou B. French Collaborative Telmisartan Study Group. Evaluation of the safety and efficacy of telmisartan and enalapril, with the potential addition of frusemide, in moderate-renal failure patients with mild-to-moderate hypertension. J Renin Angiotensin Aldosterone Syst 2001;2:246-54
   PubMed Web of Science ®Google Scholar
• Petrovic J, Petrovic D, Vukovic N, Ventricular and vascular remodelling: effects of the angiotensin II receptor blocker telmisartan and/or the angiotensin-converting enzyme inhibitor ramipril in hypertensive patients. J Int Med Res 2005;33:39-49A
   PubMed Web of Science ®Google Scholar